A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the drug continuously for about a year and 4 months and then stopping. It found that about two-thirds regained the weight they lost. A similarly designed study had comparable results for tirzepatide (Zepbound).

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,

Developed to treat diabetes, drugs like Ozempic now help fight obesity. Scientists newly honoured for working on them recall their findings.

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.

Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.